Two-thirds of the US population, particularly African Americans (AA), is at risk for inadequate or deficient 25-hydroxy-vitamin D (25(OH)VD). Epidemiological studies demonstrate an association between better health outcomes and higher blood levels of 25(OH)VD . Randomized controlled clinical trials have shown that, while supraphysiological high doses of VD are needed to achieve adequate blood levels of 25(OH)VD, not all subjects respond to them. Recent studies have also questioned the therapeutic effects of high-dose VD supplementation. Severe VD deficiency has been associated independently with the future risk of mild cognitive impairment (MCI) and dementia. A reduction in GSH and an increase in the oxidative stress levels of serum, erythrocytes, and circulating lymphocytes has been observed in MCI and Alzheimer disease, findings similar to those in VD deficient persons. Scholarly reviews conclude that excess oxidative stress is one of the major risk factors for AD and support a potential therapeutic role for L-cysteine (LC, a GSH precursor) and vitamin D (VD) supplementation in the treatment of Alzheimer disease symptoms. This application presents the investigators' design for a randomized, double-blind, placebo-controlled clinical trial to test the hypothesis that supplementation with VD in combination with L-cysteine (LC) is more successful at optimizing the statuses of 25(OH)VD [biological signatures] and simultaneously decreasing TNF-α, IR [functional or clinical outcomes], and oxidative stress, suggesting a better therapeutic approach compared with supplementation with VD alone in AA subjects.

开始日期2020-11-06

申办/合作机构

LSU Health Sciences Center

ChiCTR2000029206 / Suspended临床4期IIT

A real-world study for the efficacy and safety of Monoammonium Glycyrrhizinate and Cysteine and Sodium Chloride Injection in patients with perioperative liver injury

开始日期2020-01-06

申办/合作机构

中山大学

PACTR202401759325189 / Completed临床4期IIT

Effect of Myo-Inositol-in combination with alpha-lipoic acid and cysteine (Celine) based co-treatment on Oocyte Quality in Women with Polycystic Ovarian Syndrome Undergoing Assisted Reproductive Technology

开始日期2019-01-02

申办/合作机构-

100 项与盐酸半胱氨酸相关的临床结果

登录后查看更多信息

100 项与盐酸半胱氨酸相关的转化医学

登录后查看更多信息

100 项与盐酸半胱氨酸相关的专利（医药）

登录后查看更多信息

6,654

项与盐酸半胱氨酸相关的文献（医药）

2025-02-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Dual-Channel fluorescent detection of Biothiols: A novel probe for Distinguishing Cysteine, Homocysteine, Glutathione, and N-Acetylcysteine in cellular environments

Article

作者: Li, Haitao ; Huang, Wei ; Yin, Guoxing ; Yin, Peng ; Chen, Shiying ; He, Mengxue ; Wu, Cuiyan ; Gan, Yabing

Biothiols, including cysteine (Cys), homocysteine (Hcy), glutathione (GSH), and N-acetylcysteine (NAC), possess similar chemical structures and properties but play crucial, distinct roles in biological cells and blood serum. Imbalances in the concentrations of these biothiols are associated with various diseases, highlighting the importance of precise discrimination, especially between Cys and other biothiols. Owing to the similarity of the chemical properties of Cys, Hcy, GSH, and NAC, developing an effective methodology to differentiate these thiol compounds is challenging. In this study, we designed and synthesized a novel dual-channel fluorescent probe, hereafter referred to as CNTC, by integrating coumarin and acrylonitrile. This probe enabled the simultaneous discrimination of Cys from Hcy, GSH, and NAC, producing distinct fluorescent signals: blue for Cys and green for Hcy, GSH, and NAC. CNTC exhibited rapid response kinetics (within 30 min) and impressive detection limits of 0.31, 0.11, 0.029, and 0.032 μM for Cys, Hcy, GSH, and NAC, respectively. Furthermore, CNTC was successfully applied in the fluorescence imaging of both exogenous and endogenous Cys, Hcy, GSH, and NAC in living cells. The remarkable analytical and bioimaging capabilities of CNTCin vivo establish it as a promising tool for elucidating the pathophysiological roles of biothiols, particularly Cys, Hcy, GSH, and NAC.

2025-02-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Manipulation of defect state emission in Zn chalcogenide quantum dots and their effects on chlorophyll spectral response

Article

作者: Ük, Nida ; Nar, Ilgın ; İbiş, Özge ; Ünlü, Caner

Water soluble Zn based quantum dots (QDs) are of interest due to their biocompatibility and less toxic features. They have been frequently used in studies related to biotechnology, especially in agriculture studies. However, to control the optical properties of Zn based QDs has still been a challenge. In this work, the defect state emission of ZnSe QDs was successfully controlled through two different routes; 1) By creating a sulfur rich outer region around the Se rich core 2) By changing the capping agent. Gradient alloyed ZnSeS QDs with Se rich core and S rich outer region were successfully synthesized with two different capping agents; N-Acetyl-L-Cysteine (NAC) and 3-Mercaptopropionic Acid (3-MPA). The contribution of emission originated from surface-defects almost disappeared in NAC capped ZnSeS QDs, with causing a significant increase in photoluminescence quantum yield. The interaction between Zn based QDs with chlorophyll molecules was also investigated. The absorption capacity of chlorophylls significantly enhanced upon interaction with 3-MPA capped ZnSeS QDs. Also, the spectral response of chlorophylls could be modulated through interaction with 3-MPA capped ZnSeS QDs, which could be manipulated by using ZnSeS QDs with different chemical composition. Our results indicated that ZnSeS QDs have potential to be used in agriculture, which could act as a modulator of light-harvesting capacity of chlorophylls. The ability to modulate chlorophyll spectral responses through QD interaction opens new possibilities for optimizing light utilization in photosynthetic organisms, thereby contributing to enhanced crop yields and more efficient use of light energy in natural and artificial ecosystems.

2025-01-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Simultaneous detection of cysteine and glutathione in food with a two-channel near-infrared fluorescent probe

Article

作者: Zeng, Lintao ; Chen, Hong ; Hu, Xichao ; Duan, Ruizhe ; Wang, Jiali ; Zhang, Jin ; Li, Mingchao

L-Cysteine (Cys) and glutathione (GSH) are closely related biological species that widely exist in food and living cells. To simultaneously detect Cys and GSH from different emission channels, we developed a fluorescent probe (BDP-NBD) based on near-infrared BODIPY and 7-nitrobenzofurazan (NBD). Upon nucleophilic substitution reaction with GSH, BDP-NBD generated an emission band at 713 nm, which can be used to determine GSH (0-100 μM) with a low detection limit (34 nM). Different from GSH, BDP-NBD underwent a nucleophilic substitution-rearrangement reaction with Cys, affording two emission bands at 550 nm and 713 nm, respectively. BDP-NBD was successfully employed to quantify Cys and GSH in various food samples with good recoveries (86.6%-104.6%). Besides, BDP-NBD can image Cys and GSH in living cells from two emission channels. Therefore, this work developed a tool for the simultaneous determination of Cys and GSH in both food and living cells so as to ensure food safety and human health.

项与盐酸半胱氨酸相关的新闻（医药）

2024-11-05

·CPHI制药在线

22.5亿美元！诺华“押注”自免分子胶

关注并星标CPHI制药在线 2024 年 10 月 28 日，诺华（Novartis）宣布收购Monte Rosa Therapeutics公司一款处于临床阶段的分子胶，MRT-6160，这笔交易的包括预付款1.5亿美元，总价值超过22亿美元。诺华将获得该药的全部全球权利，该药物目前正处于免疫介导疾病的健康志愿者1期研究中，诺华将从2期开始承担开发责任。Monte Rosa公司负责1期的所有工作。 MRT-6160有效的高选择性、口服生物可利用的VAV1靶向分子胶降解剂（VAV1 MGD）。MRT-6160的体内临床前研究表明，MRT-6160能够抑制自免模型的疾病进展。体外研究中，显示出对靶标的深度降解，导致于免疫介导条件相关的细胞因子显著减少，对其他蛋白质没有可检测的影响。 VAV1：自免潜力靶点 VAV1 是 Rho 家族鸟嘌呤核苷酸交换因子，表达仅限于血液和免疫细胞，它位于T细胞受体（TCR）和B细胞受体（BCR）下游，能够介导T细胞和B细胞的激活、增殖、分化、迁移和存活。它能够激活多种转录因子，如NFAT、NF-κB、AP-1等，从而诱导多种与免疫反应相关的基因的表达。它能够与其他信号分子，如ZAP70、LAT、SLP76、ITK等相互作用，形成一个复杂的信号网络，从而调节T细胞和B细胞的功能。 VAV1在一些自身免疫性疾病中发挥重要作用，从而成为治疗这些疾病的潜在靶点。例如，在类风湿关节炎（RA）、系统性红斑狼疮（SLE）、多发性硬化（MS）等自身免疫性疾病中，VAV1被发现参与T细胞和B细胞的异常激活和功能。因此，VAV1是一个具有重要生物学功能和临床意义的靶点，它为未来开发新型抗肿瘤或抗自身免疫性疾病药物提供了新机会。今年8月，Monte Rosa在《Trends in Immunology》上发表研究 "VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases"，探讨转录因子VAV1在免疫系统中的作用。研究表明，VAV1作为一种“undruggable”蛋白，是原代人CD4+和CD8+ T细胞中TCR活化和细胞因子产生的重要正调节剂。此外，数据表明，VAV1的缺失或抑制能够调节自身免疫反应和炎症反应。基于T细胞和T/B细胞介导的关节炎和结肠炎模型的临床前数据显示，通过蛋白质降解选择性靶向VAV1具有潜在的有效性。诺华分子胶布局由于VAV1没有明确的结合口袋，开发小分子抑制剂存在诸多挑战。那么哪种药物形式可以靶向VAV1的表达或功能呢？其中基于硫唑嘌呤的活性，去设计更特异性的硫嘌呤类似物，可能为VAV1/Rac1途径阻断提供新的途径，但尚未在临床试验中进行测试；另一种新兴的模式是利用体内的泛素-蛋白酶体系统，去靶向VAV1蛋白降解。PROTAC降解剂需要能够通过不同的结合口袋同时结合靶蛋白和E3泛素连接酶的部分，导致前者的泛素化及其随后从细胞中去除。虽然有效，但这种方式对缺乏明显结合口袋的蛋白质如VAV1提出了挑战。另一种解决方案是使用分子胶，这些小分子可以黏附在酶上并改变其表面形状，从而将目标蛋白质与酶结合在一起。与PROTAC不同，分子胶不需要蛋白质中的可药用口袋，这意味着可以针对那些难以成药的蛋白质靶标进行靶向治疗。Monte Rosa Therapeutics因此开发了VAV1的分子胶MRT-6160，具有很好的药物特性。 Monte Rosa是一家明星分子胶降解剂开发公司，于2018年成立，于2021年登录纳斯达克上市。Monte Rosa公司将人工智能、结构生物学和蛋白质组学相结合，开发了一种QuEEN™平台，能够系统地识别可降解的蛋白质靶点，并开创了一种可预测、可重复的分子胶设计方法。 Monte Rosa公司的工作也吸引了罗氏的关注。2023年10月，罗氏与Monte Rosa达成战略合作和授权合作，以针对之前被认为不可成药的癌症和神经系统疾病靶点发现和开发分子胶降解剂（MGD）。事实上，诺华自己开发了一款WIZ分子胶和一种靶向CDO1的VHL分子胶。2024年7月，诺华的WIZ分子胶见刊于Science正刊，报道了首个WIZ分子胶结构dWIZ1与dWIZ2，并介绍了相关生物学机制。在人源化小鼠与NHP模型中，dWIZ-2口服给药也能有效降解WIZ，并诱导HbF的表达，且未观察到明显的不良反应。表明口服WIZ分子胶可作为作为全球可使用的镰状细胞病（SCD）/地中海贫血症的治疗方法。众所周知，镰刀型细胞贫血症（SCD）是一种普遍的、危及生命的血液疾病，可归因于β-血红蛋白的遗传突变。虽然目前已有首款获批的CRISPR/Cas9基因编辑疗法治疗该病，但该疗法涉及对DNA的基因编辑，且售价高达百万美元，SCD急需一种新的可及性更强的疗法。而WIZ分子胶作为小分子在成本和患者依从性上独具优势，有望解决全球SCD患者未满足的临床需求。目前诺华的WIZ分子胶处于IND-Enabling阶段。目前主要开发的分子胶主要是依赖CRBN 泛素连接酶。其代表性药物则是IMIDs 三兄弟：Thalidomide, Lenalidomide以及Pomalidomide，其销售额常年超过百亿美元。而新进开发的基于CRBN的分子胶更多的集中在已经报道的可被降解的靶点。虽然针对CRBN分子胶水的研究目前如火如荼，分子胶水的发展对于新的E3泛素连接酶的需求也是与日俱增。 2024年1月，诺华公司在预印本网站bioRxiv上发表了题目为“A small molecule VHL molecular glue degrader for cysteine dioxygenase 1”的文章，介绍了一种靶向CDO1的VHL分子胶，这也是第一例报道的依赖VHL E3 泛素连接酶的分子胶，它能促进 VHL-配体-CDO1 三元复合物的组装，从而实现 VHL 依赖性降解内源性 CDO1。参考来源 1.Markus F. Neurath and Leslie J. Berg, “VAV1 as a Putative Therapeutic Target in Autoimmune and Chronic Inflammatory Diseases,” Trends in Immunology 45, no. 8 (August 2024): 580–96, https://doi-org.libproxy1.nus.edu.sg/10.1016/j.it.2024.06.004. 2.Ali A. Zarrin et al., “Kinase Inhibition in Autoimmunity and Inflammation,” Nature Reviews Drug Discovery 20, no. 1 (January 2021): 39–63, https://doi-org.libproxy1.nus.edu.sg/10.1038/s41573-020-0082-8. END 【智药研习社线上研习会报名】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

细胞疗法并购免疫疗法临床1期临床2期

2024-10-30

·生物探索

Nat Commun | 魏民/王杨团队与巴雪青团队合作揭示甲硫氨酸-SAM代谢依赖的泛醌合成对铁死亡诱导中ROS的积累至关重要

引言铁死亡（Ferroptosis）是区别于细胞凋亡、坏死、自噬的一种新型调节性的细胞死亡方式【1】，由铁依赖的脂质过氧化物积累所导致，铁死亡的诱发在许多疾病（如缺血再灌注心肌损伤、神经退行性病变、自身免疫性以及传染性疾病）中起关键致病作用【2,3】，同时也是临床中治疗肿瘤的新型手段【4,5】。诱发细胞铁死亡的主要因素包括ROS（•OH）、含有多不饱和脂肪酸的磷脂（PUFA-PL）和Fe2+，因而铁死亡严格受到氧化还原稳态、铁代谢和脂代谢的调控。近年来，糖代谢和氨基酸代谢对铁死亡的调控作用也日渐凸显，但具体精细的调节机制很大程度上仍然未知。 2024年10月17日，东北师范大学分子表观遗传学教育部重点实验室魏民/王杨团队与巴雪青团队合作在Nature Communications上发表了题为Methionine-SAM metabolism-dependent ubiquinone synthesis is crucial for ROS accumulation in ferroptosis induction的研究论文，系统地报道了甲硫氨酸衍生的S-腺苷甲硫氨酸（S-adenosylmethionine, SAM）促进电子载体泛醌（Ubiquinone, UQ）的合成及线粒体ROS的产生，是细胞发生铁死亡的必要条件。铁死亡的根本诱因是由于细胞的氧化还原平衡被打破，导致ROS的大量积累，进而产生过量的脂质过氧化物所致。细胞内的抗氧化系统可还原脂质过氧化物防御细胞发生铁死亡，其中Cyst(e)ine/GSH/GPX4系统是目前公认的最主要的铁死亡防御系统。过氧化物酶（GPX4）利用其底物谷胱甘肽（GSH）提供的电子将过氧化的脂质还原为无毒性的脂质醇，从而达到清除脂质过氧化物的目的，使细胞免于铁死亡【6-10】。GSH是Cyst(e)ine/GSH/GPX4系统中核心的抗氧化物质，由半胱氨酸（Cysteine, Cys）、甘氨酸和谷氨酸三种氨基酸组成。虽同为非必需氨基酸，但Cys的巯基是GSH抗氧化能力的来源，正因如此Cys是GSH合成的限制性底物，Cys的可获得性是GSH合成的限制因素。已知细胞中存在两种途径获取Cys：以胱氨酸为基础的半胱氨酸的外源吸收途径和以甲硫氨酸（Methionine, Met）为基础的半胱氨酸的内源合成途径。然而，在目前铁死亡研究中，仅限制Cys外源吸收途径即可诱导细胞发生铁死亡。那么，以Met为基础的Cys内源合成途径在此过程中为什么无法有效防御铁死亡呢？Met与铁死亡的发生到底是什么关系呢？该研究发现，即使使用远高于生理浓度的Met，也并没有缓解细胞内Cys和GSH的耗竭，同时也未对细胞铁死亡产生缓解作用，这说明，由Met生成的Cys的途径可能是受阻的。随后该研究发现，由Met生成的Cys的内源合成途径具有肝脏组织特异性。同时，研究还意外地发现，Met不仅不能通过内源合成途径生成Cys抑制细胞铁死亡，反而Met的存在是细胞铁死亡发生所必需的，Met衍生的SAM是调节铁死亡的关键代谢物，以SAM为基础的甲基化修饰作用促进了线粒体电子传递链中电子载体UQ的合成及线粒体ROS的产生，从而参与铁死亡的发生。小鼠体内的实验结果显示，注射SAM能增效铁死亡诱导剂Imidazole Ketone Erastin（IKE）引起的肿瘤细胞内铁死亡水平并进一步抑制肿瘤生长；灌胃MAT2A的抑制剂FIDAS-5，即抑制Met向SAM的转化，能降低小鼠心肌细胞铁死亡水平并缓解阿霉素Doxorubicin（DOX）诱导的心肌损伤。模式图（Credit: Nature Communications）综上所述，该研究从探究甲硫氨酸向半胱氨酸转化的内源合成途径在防御铁死亡中的可能作用切入，但预期之外地发现Met不但不能通过合成半胱氨酸抑制铁死亡，反而通过增加电子载体泛醌的合成贡献于线粒体ROS的产生和积累，且对铁死亡的发生至关重要。此项研究为深刻认识氨基酸调控铁死亡的作用提供新理解，并为铁死亡相关病理干预提供新策略。参考文献 1. Dixon, S.J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072 (2012). 2. Gao, M., Monian, P., Quadri, N., Ramasamy, R. & Jiang, X. Glutaminolysis and Transferrin Regulate Ferroptosis. Mol Cell 59, 298-308 (2015). 3. Friedmann Angeli, J.P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 16, 1180-1191 (2014). 4. Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57-62 (2015). 5. Badgley, M.A. et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science 368, 85-+ (2020). 6. Ingold, I. et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. CELL 172, 409-422 (2018). 7. Tang, D., Chen, X., Kang, R. & Kroemer, G. Ferroptosis: molecular mechanisms and health implications. Cell research 31, 107-125 (2021). 8. Hassannia, B., Vandenabeele, P. & Vanden Berghe, T. Targeting Ferroptosis to Iron Out Cancer. Cancer cell 35, 830-849 (2019). 9. Dixon, S. & Olzmann, J. The cell biology of ferroptosis. Nature reviews. Molecular cell biology (2024). 10. Stockwell, B. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell 185, 2401-2421 (2022). https://www-nature-com.libproxy1.nus.edu.sg/articles/s41467-024-53380-5 责编|探索君排版|探索君来源|BioArt End 往期精选围观一文读透细胞死亡(Cell Death) | 24年Cell重磅综述（长文收藏版）热文 Cell | 是什么决定了细胞的大小？热文 Nature | 2024年值得关注的七项技术热文 Nature | 自身免疫性疾病能被治愈吗？科学家们终于看到了希望热文 CRISPR技术进化史 | 24年Cell综述

核酸药物申请上市

2024-10-22

·药通社

【论药海南】专供特色化学原料药-山西阳和药业，涉及呼吸系统、消化系统等领域

2023年12月3-4日 2024MAH&DDS制剂合作大会·海南站展位号：37号公司简介山西阳和药业有限公司成立于2017年，坐落于山西省大同市阳高县龙泉工业园区。公司注册资本5100万元，总占地面积100亩。阳和药业作为化学原料药的商业化生产基地，专业从事特色化学原料药的研发、生产、销售。公司现拥有多条原料药生产线，产品涉及呼吸系统、消化系统等多个领域。目前公司可大批量生产乙酰半胱氨酸、间苯三酚、间苯三酚三甲醚、聚乙烯醇等原料药。 COMPANY PROFILE Shanxi Yanghe Pharmaceutical Co., Ltd. was established in 2017 and is located in Longquan lndustrial Park, Yanggao County, Datong city, shanxi Province. The registered capital of the company is 51 million yuan, and the total area is 100 acres.As a commercial production base of chemical APls, Yanghe Pharmaceutical specializes in the R&D, production and sales of specialty chemical APls. The company now has a number of API production lines, and its products involve respiratory system, digestive system and other fields. At present,the company can produce acetylcysteine, resorcinol, and resorcinol trimethyl ether in large quantities, polyvinyl alcohol and other APls. 公司团队公司拥有一支年轻有干劲的新型团队；建立了完善的生产和质量管理体系；公司建有多个原料药多功能车间，实现从小试研究、中试放大、注册申报、大规模生产的一条龙服务；严格的质量控制，完善的检验设施和仪器设备，严密的质量保证系统，能够有效保障法规符合性、CFDl注册核查和客户审计的要求。 COMPANY TEAM The company has a young and energetic new team, has established a sound production and QMS system, the company has built a number of APl multifunctional workshops, to achieve a small test research, pilot scale-up, registration declaration, large-scale production one-stop service, strict QC, perfect inspection facilities and equipment, strict QA system, can effectively ensure regulatory compliance,CFDl registration verification and customer audit requirements. 01 乙酰半胱氨酸化学名：N-乙酰基-L-半胱氨酸 CAS No.: 616-91-1 登记号：Y20210001235 用途：呼吸系统药物，具有祛痰的作用，其注射液用于肝衰竭早期治疗，也可用于配置复合氨基酸输液、特医食品及保健品。符合ChP2020年版、BP2022、EP10.8、JPX VlII、USP-NF2022药典标准；已获得GMP、CP Chemical name: N-acetyl-L-cysteine CAS No.: 616-91-1 Registration No.: Y20210001235 Uses: Respiratory system drug, with expectorant effect, its injection for the early treatment of liver failure, can also be used to configure complex amino acid infusion, special medical food and health care products. In accordance with ChP2020、BP2022、EP10.8、JPX VlII、USP-NF2022；GMP and CP have been obtained 02 间苯三酚三甲醚化学名：1，3，5-三甲氧基苯 CAS NO.: 621-23-8 登记号：Y20220000338 用途：消化系统和胆道功能障碍引起的急性痉挛性疼痛；急性痉挛性尿道、膀胱、肾绞痛；妇科痉挛性疼痛已获得GMP、CP Chemical name: 1,3,5-Trimethoxybenzene CAS No.: 621-23-8 Registration No.: Y20220000338 Uses: Acute spasmodic pain caused by digestive system and biliary tract dysfunction; Acute spastic colic of urethra, bladder and kidney; Gynecologic spasmodic pain GMP and CP have been obtained 03 间苯三酚化学名：苯基-1，3，5-三酚二水合物 CAS No.: 6099-90-7 登记号：Y20220000471 用途：消化系统和胆道功能障碍引起的急性痉挛性疼痛；急性痉挛性尿道、膀胱、肾绞痛；妇科痉挛性疼痛符合BP2022、EP10. 8药典标准；已获得GMP、CP Chemical name: Benzene-1,3,5-triol dihydrate CAS No.: 6099-90-7 Registration No.: Y20220000471 Uses: Acute spasmodic pain caused by digestive system and biliary tract dysfunction; Acute spastic colic of urethra, bladder and kidney; Gynecologic spasmodic pain In accordance with BP2022, EP10.8；GMP and CP have been obtained 04 聚乙烯醇化学名：聚乙烯醇 CAS NO.: 9002-89-5 用途：用于润滑和滋润眼睛表面，有助于暂时缓解干眼症（DED）或环境因素引起的干燥、刺激、灼热、不适和/或任何其他症状符合ChP2020年版、BP2022、EP10.8、USP-NF2022药典标准；已获得GMP Chemical name: Poly(vinyl alcohol) macromolecule CAS No.: 9002-89-5 Use: To lubricate and moisturize the surface of the eye to help temporarily relieve dryness, irritation, burning, discomfort and/or any other symptoms of dry eye (DED) or environmental factors。 In accordance with ChP2020、BP2022、EP10.8、USP-NF2022；GMP have been obtained 联系方式周女士13306586060 薛女士15958675001 点击查看大会详情 ▽ 立即扫码报名 ▽

100 项与盐酸半胱氨酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02326	盐酸半胱氨酸	A16AA	DB00151

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
营养紊乱	美国	Exela Pharma Sciences LLC	2019-04-16
膳食补充剂	美国	Hospira, Inc.	1986-10-22
肿瘤	中国	陕西汉唐制药有限公司	1982-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASGCT2020	N/A	-	-	Glutamate-Cysteine Ligase Modifi er Subunit	餘醖餘夢窪窪淵鹽齋範(壓鬱廠窪憲餘製壓選築) = Cell death and proliferation in all cell cultures were in an AUC-dependent manner 鑰衊衊淵餘淵壓衊糧膚 (鹽膚築鹽鬱遞觸憲積鏇 ) 更多	-	2020-04-28
				Glutamate-Cysteine Ligase Modifi er Subunit
ARVO2015	N/A	-	-	L-cysteine	鹽積糧壓範繭艱積襯鏇(範齋簾憲選繭衊齋齋夢) = 艱醖窪選廠築觸齋鹹範窪齋築遞蓋襯鹽獵簾蓋 (糧構獵襯獵選鬱鏇顧觸 )	-	2015-06-01
				Anandamide	鹽積糧壓範繭艱積襯鏇(範齋簾憲選繭衊齋齋夢) = 窪膚遞鬱選淵網襯顧憲窪齋築遞蓋襯鹽獵簾蓋 (糧構獵襯獵選鬱鏇顧觸 )
FP022 (ERA2012)	N/A	homocysteine \| acetylcysteine	-	Acetylcysteine	淵繭糧鹽製簾醖製選糧(餘鏇壓鏇艱廠窪選鹹鬱) = 遞夢餘獵窪鹹鏇繭蓋構壓簾簾願鹹襯廠鹹鑰網 (衊衊顧範糧膚襯繭餘網 )	积极	2012-05-01
				Cation-channel blockers	淵繭糧鹽製簾醖製選糧(餘鏇壓鏇艱廠窪選鹹鬱) = 夢網艱艱鹽衊顧糧齋選壓簾簾願鹹襯廠鹹鑰網 (衊衊顧範糧膚襯繭餘網 )
ARVO2011	N/A	视网膜疾患 CD34+	-	Cysteine-Rich Protein 61 (CCN1/Cyr61)	襯製窪襯糧願壓醖憲壓(觸夢構襯齋窪廠蓋艱齋) = 積艱艱網鹹廠鏇衊艱鬱顧製鏇鏇願簾壓齋觸艱 (窪窪願膚窪獵觸衊淵襯 )	-	2011-04-01
				Cysteine-Rich Protein 61 (CCN1/Cyr61)	襯製窪襯糧願壓醖憲壓(觸夢構襯齋窪廠蓋艱齋) = 繭餘憲齋餘廠餘醖鹹鏇顧製鏇鏇願簾壓齋觸艱 (窪窪願膚窪獵觸衊淵襯 )